pargyline has been researched along with safinamide in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 3 (60.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boppana, K; Dubey, PK; Jagarlapudi, SA; Rambabu, G; Vadivelan, S | 1 |
| Almos, T; Edmondson, DE; Massari, ME; Rojas, RJ; Scott, R | 1 |
| Mostert, S; Petzer, A; Petzer, JP | 2 |
| Hoshi, K; Kamauchi, H; Mabashi, R; Nagai, J; Sugita, Y; Takao, K; Takemura, Y; Uesawa, Y | 1 |
5 other study(ies) available for pargyline and safinamide
| Article | Year |
|---|---|
Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models.
Topics: Catalytic Domain; Drug Design; Humans; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Structure-Activity Relationship | 2009 |
Reversible and irreversible small molecule inhibitors of monoamine oxidase B (MAO-B) investigated by biophysical techniques.
Topics: Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Small Molecule Libraries; Thermodynamics | 2015 |
Inhibition of monoamine oxidase by benzoxathiolone analogues.
Topics: Benzoxazoles; Humans; Inhibitory Concentration 50; Kinetics; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Protein Binding; Protein Isoforms; Structure-Activity Relationship | 2016 |
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase.
Topics: Benzoquinones; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Structure-Activity Relationship | 2017 |
Synthesis and biological evaluation of 3-styrylchromone derivatives as selective monoamine oxidase B inhibitors.
Topics: Chromones; Dose-Response Relationship, Drug; Humans; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship; Recombinant Proteins | 2021 |